Azenta (AZTA) Stock Price, News & Analysis

Company Overview

Azenta, Inc. (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services. Researchers and biopharma companies rely on these capabilities for applications ranging from basic research and drug discovery to precision medicine. The company’s facility network supports high-throughput processing, quality control and regulatory compliance, addressing needs across genomics, transcriptomics and proteomics workflows.

Headquartered in Chelmsford, Massachusetts, Azenta serves a global customer base that includes pharmaceutical and biotechnology firms, academic institutions and contract research organizations. The company operates multiple facilities across North America, Europe and Asia, enabling scalable sample management and genomics projects. Its solutions are designed to support complex supply chains for cell and gene therapies, biologics development and large-scale biobanking initiatives.

Azenta completed its spin-off from Brooks Automation in February 2021, establishing itself as a standalone public company focused on the accelerating demands of life sciences research. The company is led by President and Chief Executive Officer Joseph L. Hawkins, whose leadership team continues to expand Azenta’s footprint in sample management automation and genomics services worldwide. Through ongoing investments in technology and facility capacity, Azenta aims to drive innovation in life sciences and deliver reliable, end-to-end solutions to its customers.

Key Stats

• Today's Range: $20.65 to $21.29
• 50-Day Range: $16.02 to $26.46
• 52-Week Range: $15.93 to $41.73
• Volume: 300,730 shs
• Average Volume: 995,961 shs
• Market Capitalization: $977.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.50
• Consensus Rating: Hold

Azenta Stock Analysis - MarketRank™

Azenta scored higher than 38% of companies evaluated by MarketBeat, and ranked 682nd out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Azenta has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Azenta has a consensus price target of $39.50, representing about 86.2% upside from its current price of $21.21.

Amount of Analyst Coverage

Azenta has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Azenta is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Azenta is -5.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Azenta has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.51% of the float of Azenta has been sold short.

Short Interest Ratio / Days to Cover

Azenta has a short interest ratio ("days to cover") of 7.46.

Change versus previous month

Short interest in Azenta has recently increased by 7.86%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azenta does not currently pay a dividend.

Dividend Growth

Azenta does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.38

News Sentiment

Azenta has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Azenta this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azenta insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.90% of the stock of Azenta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.08% of the stock of Azenta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/27/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:AZTA
• CIK: 933974
• Web: www.brooks.com
• Phone: (978) 262-2400
• Fax: 978-262-2500
• Employees: 3,000
• Year Founded: 1978

Price Target and Rating

• Average Price Target for Azenta: $39.50
• High Price Target: $45.00
• Low Price Target: $33.00
• Potential Upside/Downside: +86.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.76 million
• Net Margins: -30.49%
• Pretax Margin: -25.28%
• Return on Equity: 1.23%
• Return on Assets: 1.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.83
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $593.82 million
• Price / Sales: 1.65
• Cash Flow: $1.91 per share
• Price / Cash Flow: 11.13
• Book Value: $33.73 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: 46,090,000
• Free Float: 41,069,000
• Market Cap: $977.75 million
• Optionable: Optionable
• Beta: 1.43